Skip to main content

Advertisement

Table 1 Trial and patient summary characteristics for the 102 eligible RCTs (36,058 patients) of second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR

From: Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

Trial characteristics No. of trials (%)
Phase of trial
 II 48 (47)
 III 53 (52)
 Unclear 1 (1)
No. of centers
 Multi-center 88 (86)
 Single-center 7 (7)
 Unclear 7 (7)
Funding source
 Industry 69 (68)
 Non-industry 13 (13)
 Both 2 (2)
 Not reported 18 (17)
No. of patients (median [Q1–Q3]; mean) 167 [105–528]; 354
Line therapy
 Second-line only 50 (49)
 Second- and third-line 41 (40)
  Proportion of patients with third-line therapya 31%
 Not specified 11 (11)
Population characteristics
 Geographic origin
  Most Western patientsb 54 (53)
  Asian patients only 26 (25)
  Not specified 22 (22)
   Proportion of Asian patientsa 14%
 Trials in specific histology subtype
  NSCC 20 (20)
  SCC 4 (4)
   Proportion of patients with SCCa 27%
 Molecular characteristics at baseline
  Unknown status for EGFR 93 (91)
  EGFR wild-type 6 (6)
  KRAS mutation 3 (3)
Patient characteristicsa
 Age, years 61
 Male 62%
 Stage IV cancer 81%
 Patients PS 2 8%
 Former or current smoker 80%
 Patients receiving second-line treatment 85%
  1. aMean over trials
  2. b ≥ 60% of Caucasian patients
  3. EGFR epidermal growth factor receptor, NSCC non-squamous cell carcinoma, PS Eastern Cooperative Oncology Group performance status, SCC squamous cell carcinoma